Overview

s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Efficacy and Safety of s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension:a Randomized,Double-blind,Placebo-controlled,Multicenter Phase II Clinical Trial
Phase:
Phase 2
Details
Lead Sponsor:
Shenzhen People's Hospital
Treatments:
Olmesartan
Olmesartan Medoxomil